Previous 10 | Next 10 |
2023-07-19 10:22:17 ET Gainers: Panbela Therapeutics ( PBLA ) +36% . 60 Degrees Pharmaceuticals ( SXTP ) +20% . CareMax ( CMAX ) +20% . Biodexa Pharmaceuticals ( BDRX ) +13% . bluebird bio ( BLUE ) +13% . Losers: Amar...
2023-07-19 10:03:43 ET Panbela Therapeutics ( NASDAQ: PBLA ) shares jumped nearly 40% in early trading on Wednesday after the company said it had divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds. Under the deal, Panbela w...
MINNEAPOLIS and LOUISVILLE, Ky., July 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has divested certain assets in its eflornit...
2023-07-17 08:55:08 ET Panbela Therapeutics ( NASDAQ: PBLA ) said Monday it received a patent in Australia for a novel process to produce SBP-101, its lead investigational product to treat pancreatic cancer tumors. The company was issued the Australian patent 201921...
MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an Issue Notification for the Australian paten...
MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the independent Data Safety Monitoring Board (DSMB) of the Phas...
Panbela Therapeutics (NASDAQ: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has closed on its previously announced public offering. The offering consisted of 2,270,000 shares of its common stock or prefunded...
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the SWOG Cancer Research Network’s PACES S0820 Phase III t...
MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for CPP...
MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering ...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...